Skip to main content

Henlius Reports NDA for its PD-L1 Inhibitor Accepted for China Review

Shanghai Henlius Biotech said the NDA for its novel anti-PD-L1 candidate has been accepted for review by China 's NMPA. Serplulimab injection (HLX10) was tested in patients with unresectable or metastatic microsatellite instability-high (MSI-H) solid tumors who did not respond to the standard therapy. It has the potential to be the first anti-PD-1 mAb approved for MSI-H solid tumors in  China , the company said. So far, Henlius, an affiliate of Fosun Pharma, has launched three biosimilars in China . More details.... Stock Symbols: (HK:2696) (SHA: 600196; HK: 02196) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.